Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

References

• Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: The GATAC trial. Gastric Cancer 2010;13:155–61.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non- gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–63.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–44.
   PubMed Web of Science ®Google Scholar
• Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6.
   PubMed Web of Science ®Google Scholar
• Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–5.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370–7.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol 2010;101:457–64.
   PubMed Web of Science ®Google Scholar
• Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 2005;9:1346–53.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18:1575–81.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42.
   PubMed Web of Science ®Google Scholar
• Vazquez Vde L, Sugarbaker PH. Cholecystectomy, lesser omentectomy, and stripping of the omental bursa: A peritonectomy procedure. J Surg Oncol 2003;84:45–9.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Averbach AM, Jacquet P, Stephens AD, Stuart OA. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. Cancer Treat Res 1996;82:415–21.
   PubMedGoogle Scholar
• Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
   Google Scholar
• NCI NIH DHHS. DTCD, Common terminology criteria for adverse events v3.0 (CTAE). Cancer Therapy Evaluation Program, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267–72.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Participants, perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008;98:273–6.
   PubMed Web of Science ®Google Scholar
• Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: Prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol 2012;38: 509–15.
   PubMed Web of Science ®Google Scholar
• van Leeuwen BL, Graf W, Pahlman L, Mahteme H. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008;15: 745–53.
   PubMed Web of Science ®Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22: 3284–92.
   PubMed Web of Science ®Google Scholar
• Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14:509–14.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1,290 patients. Cancer 2009; 116:5608–18.
   Web of Science ®Google Scholar
• Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009;250: 878–87.
   PubMed Web of Science ®Google Scholar
• Sun Z, Xu YY, Wang ZN, Zhu Z, Zhang H, Huang BJ, et al. Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery. Ann Surg Oncol 2011;18:1068–80.
   PubMed Web of Science ®Google Scholar
• Greene F, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. New York: Springer; 2002.
   Google Scholar
• Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: Results of 21 cases. Ann Surg Oncol 2009; 16:345–51.
   PubMed Web of Science ®Google Scholar
• Fanelli MF, Silva MJ, de Paiva TF, Jr., Chinen LT, Guimaraes AP, Gimenes DL, et al. Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil. Int J Clin Oncol 2009;14:326–31.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study. Gastric Cancer 2003;6: 142–5.
   PubMedGoogle Scholar
• Kodama I, Koufuji K, Kawabata S, Tetsu S, Tsuji Y, Takeda J, et al. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg 1995;80:45–8.
   PubMed Web of Science ®Google Scholar
• Safi F, Kuhns V, Beger HG. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int J Biol Markers 1995;10:100–6.
   PubMed Web of Science ®Google Scholar
• Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999;29:550–5.
   PubMed Web of Science ®Google Scholar
• Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000;16:105–10.
   PubMed Web of Science ®Google Scholar
• Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001;22:318–22.
   PubMed Web of Science ®Google Scholar
• Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepato-gastroenterology 2002;49:1157–60.
   PubMed Web of Science ®Google Scholar
• Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999;57:55–62.
   PubMed Web of Science ®Google Scholar
• Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, et al. An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer. Oncol Rep 2010;24:1645–52.
   PubMed Web of Science ®Google Scholar
• Rossi CR, Pilati P, Mocellin S, Foletto M, Ori C, Innocente F, et al. Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma. Suppl Tumori 2003;2:S54–7.
   Google Scholar
• Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15:754–63.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Tentes AA, Vaxevanidou A, Korakianitis OS, Rogdakis A, Mirelis CG, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. J Buon 2008;13: 205–10.
   Google Scholar